NICE speeds BI's Giotrif through appraisal process
This article was originally published in Scrip
Executive Summary
NICE has recommended Boehringer Ingelheim's lung cancer drug Giotrif (afatinib) in final draft recommendation, skipping one of the usual consultation phases in order to get the drug to patients in England and Wales faster.